Tanvex BioPharma, Inc. (6541.TW)

TWD 58.5

(-3.62%)

Total Assets Summary of Tanvex BioPharma, Inc.

Tanvex BioPharma, Inc.'s latest annual total assets in 2023 was 2.76 Billion TWD , down -19.19% from previous year.
Tanvex BioPharma, Inc.'s latest quarterly total assets in 2024 Q2 was 3.38 Billion TWD , up 22.53% from previous quarter.
Tanvex BioPharma, Inc. reported annual total assets of 3.41 Billion TWD in 2022, down -27.45% from previous year.
Tanvex BioPharma, Inc. reported annual total assets of 4.71 Billion TWD in 2021, up 7.8% from previous year.
Tanvex BioPharma, Inc. reported quarterly total assets of 2.76 Billion TWD for 2024 Q1, up 0.07% from previous quarter.
Tanvex BioPharma, Inc. reported quarterly total assets of 3.74 Billion TWD for 2023 Q2, up 27.01% from previous quarter.

Annual Total Assets Chart of Tanvex BioPharma, Inc. (2023 - 2013)

Historical Annual Total Assets of Tanvex BioPharma, Inc. (2023 - 2013)

Year	Total Assets	Total Assets Growth
2023	2.76 Billion TWD	-19.19%
2022	3.41 Billion TWD	-27.45%
2021	4.71 Billion TWD	7.8%
2020	4.37 Billion TWD	22.38%
2019	3.57 Billion TWD	-20.22%
2018	4.47 Billion TWD	12.73%
2017	3.97 Billion TWD	2.6%
2016	3.87 Billion TWD	146.74%
2015	1.56 Billion TWD	139.7%
2014	654.73 Million TWD	34.37%
2013	487.27 Million TWD	0.0%

Year	Total Assets	Total Assets Growth
2024 Q2	3.38 Billion TWD	22.53%
2024 Q1	2.76 Billion TWD	0.07%
2023 Q2	3.74 Billion TWD	27.01%
2023 FY	2.76 Billion TWD	-19.19%
2023 Q4	2.76 Billion TWD	-19.75%
2023 Q1	2.94 Billion TWD	-13.85%
2023 Q3	3.44 Billion TWD	-7.98%
2022 Q2	4.14 Billion TWD	-6.87%
2022 Q4	3.41 Billion TWD	-13.93%
2022 Q3	3.97 Billion TWD	-4.11%
2022 Q1	4.44 Billion TWD	-5.6%
2022 FY	3.41 Billion TWD	-27.45%
2021 FY	4.71 Billion TWD	7.8%
2021 Q4	4.71 Billion TWD	-7.23%
2021 Q1	3.88 Billion TWD	-11.14%
2021 Q2	3.46 Billion TWD	-10.88%
2021 Q3	5.08 Billion TWD	46.72%
2020 Q4	4.37 Billion TWD	118.96%
2020 Q1	2.99 Billion TWD	-16.24%
2020 Q2	2.46 Billion TWD	-17.72%
2020 Q3	1.99 Billion TWD	-18.89%
2020 FY	4.37 Billion TWD	22.38%
2019 Q1	4.39 Billion TWD	-1.81%
2019 Q2	3.86 Billion TWD	-12.13%
2019 FY	3.57 Billion TWD	-20.22%
2019 Q4	3.57 Billion TWD	11.02%
2019 Q3	3.21 Billion TWD	-16.71%
2018 Q4	4.47 Billion TWD	-8.74%
2018 FY	4.47 Billion TWD	12.73%
2018 Q3	4.9 Billion TWD	50.18%
2018 Q2	3.26 Billion TWD	-8.56%
2018 Q1	3.57 Billion TWD	-10.05%
2017 Q4	3.97 Billion TWD	48.22%
2017 FY	3.97 Billion TWD	2.6%
2017 Q1	3.27 Billion TWD	-15.51%
2017 Q2	2.98 Billion TWD	-8.86%
2017 Q3	2.68 Billion TWD	-10.12%
2016 Q3	4.03 Billion TWD	-7.64%
2016 Q1	- TWD	-100.0%
2016 FY	3.87 Billion TWD	146.74%
2016 Q2	4.36 Billion TWD	0.0%
2016 Q4	3.87 Billion TWD	-4.0%
2015 Q4	1.56 Billion TWD	0.0%
2015 Q2	1.94 Billion TWD	0.0%
2015 Q1	1.94 Billion TWD	197.6%
2015 FY	1.56 Billion TWD	139.7%
2014 FY	654.73 Million TWD	34.37%
2014 Q4	654.73 Million TWD	0.0%
2014 Q3	654.73 Million TWD	0.0%
2014 Q1	- TWD	0.0%
2013 FY	487.27 Million TWD	0.0%

Peer Total Assets Comparison of Tanvex BioPharma, Inc.

Name	Total Assets	Total Assets Difference
Apex Biotechnology Corp.	2.29 Billion TWD	-20.305%
Sinphar Pharmaceutical Co.,Ltd.	6.25 Billion TWD	55.793%
Panion & Bf Biotech Inc.	3.23 Billion TWD	14.583%
Chunghwa Chemical Synthesis & Biotech Co., Ltd.	5.17 Billion TWD	46.566%
GenMont Biotech Incorporation	1.65 Billion TWD	-67.157%
Abnova (Taiwan) Corporation	1.35 Billion TWD	-103.829%
Adimmune Corporation	9.48 Billion TWD	70.864%
Polaris Group	9.09 Billion TWD	69.626%
Energenesis Biomedical CO.,LTD.	828.57 Million TWD	-233.515%
UnicoCell Biomed Co., Ltd.	685.92 Million TWD	-302.87%
PELL Bio-Med Technology Co. Ltd.	1.41 Billion TWD	-94.859%